Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032

Activating mutations in BRAF kinase are common in melanomas. Clinical trials with PLX4032, the mutant-BRAF inhibitor, show promising preliminary results in patients selected for the presence of V600E mutation. However, activating V600K mutation is the other most common mutation, yet patients with th...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Rubinstein, Jill C, Sznol, Mario, Pavlick, Anna C, Ariyan, Stephan, Cheng, Elaine, Bacchiocchi, Antonella, Kluger, Harriet M, Narayan, Deepak, Halaban, Ruth
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2010
Konular:
Commentary
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2917408/
https://ncbi.nlm.nih.gov/pubmed/20630094
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-8-67
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller